Home > Healthcare > Pharmaceuticals > Clinical Nutrition > Intravenous Solutions Market

Intravenous Solutions Market Size

  • Report ID: GMI8359
  • Published Date: Mar 2024
  • Report Format: PDF

Intravenous Solutions Market Size

Intravenous Solutions Market size was valued at USD 13 billion in 2023 and is expected to grow at a CAGR of 7.5% over the analysis period, driven by factors such as the growing geriatric population, increasing cases of malnutrition, and high prevalence of preterm births.

 

Also, increase in the prevalence of diseases, such as neurological conditions, gastrointestinal diseases, and cancer where intravenous solutions serve as the primary sources of energy for patients, is driving the market growth. For instance, as reported by the World Health Organization, global cancer incidence, measured in cases per year, reached approximately 20 million in 2022 and is projected to rise to 35 million by 2050. Thereby, increasing prevalence of such diseases increases the demand for intravenous solutions.

 

Intravenous (IV) solutions, also known as intravenous fluids or IV fluids, are sterile liquids that are administered directly into the bloodstream via a vein. These solutions are used to provide hydration, deliver medications, maintain electrolyte balance, and supply nutrients to patients who are unable to take fluids or medications orally.

 

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Intravenous solutions industry size was USD 13 billion in 2023 and is expected to reach USD 24.8 billion by 2032, driven by the growing geriatric population, increasing cases of malnutrition, and high prevalence of preterm births.

The total parenteral nutrition type segment reached a revenue of USD 8.7 billion in 2023 and will grow significantly through 2032, due to its role in providing complete nutrition to patients who cannot consume food orally.

North America recorded 42.7% of the intravenous solutions industry share in 2023 and is expected to dominate throughout 2024 and 2032 attributed to the advanced healthcare infrastructure in the region, a strong focus on patient care, and high healthcare expenditure.

Ajinomoto Co., Inc., Amanta Healthcare, Axa Parenterals Ltd, B. Braun Melsungen AG, Baxter International Inc., Fresenius Kabi USA, LLC, Grifols, S.A., ICU Medical. Inc., JW Life Science, Otsuka Pharmaceutical Co., Ltd, and Pfizer, Inc.

Intravenous Solutions Market Scope

Buy Now


Premium Report Details

  • Base Year: 2023
  • Companies covered: 11
  • Tables & Figures: 310
  • Countries covered: 20
  • Pages: 180
 Download Free Sample